Drug Profile
AMT 060
Alternative Names: AAV5-FIX; AAV5-hFIX; AMT-060Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Amsterdam Molecular Therapeutics
- Developer St. Jude Childrens Research Hospital; uniQure; University College London
- Class Antihaemorrhagics; Gene therapies
- Mechanism of Action Factor IX replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Haemophilia B
Most Recent Events
- 05 Dec 2020 Adverse events and safety data from a phase I/II trial in Hemophilia B presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology(ASH-Hem-2020)
- 13 Nov 2020 uniQure initiates a phase I/II extension trial in Haemophilia B in Denmark (IV) (EudraCT2020-000739-28)
- 07 Dec 2019 Efficacy and adverse events data from a phase I/II trial in Haemophilia B presented at the 61st Annual Meeting and Exposition of the American Society of Hematology (ASH-2019)